Nivolumab + Temozolomide
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Brain Cancer
Conditions
Brain Cancer
Trial Timeline
Mar 1, 2016 → Mar 4, 2022
NCT ID
NCT02617589About Nivolumab + Temozolomide
Nivolumab + Temozolomide is a phase 3 stage product being developed by Ono Pharmaceutical for Brain Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02617589. Target conditions include Brain Cancer.
What happened to similar drugs?
5 of 17 similar drugs in Brain Cancer were approved
Approved (5) Terminated (2) Active (12)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02667587 | Phase 3 | Completed |
| NCT02617589 | Phase 3 | Completed |
Competing Products
20 competing products in Brain Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Abemaciclib + Endocrine therapy | Eli Lilly | Phase 1/2 | 39 |
| Duloxetine + Sugar pill | Eli Lilly | Phase 2 | 27 |
| Neurosteroid enantiomer | Oragenics | Phase 2 | 32 |
| Patritumab deruxtecan | Daiichi Sankyo | Phase 2 | 27 |
| filgrastim + exatecan mesylate | Daiichi Sankyo | Phase 1 | 29 |
| Eribulin Mesylate | Eisai | Phase 1 | 29 |
| Pembrolizumab + Lenvatinib | Eisai | Phase 2 | 42 |
| Palonosetron (Aloxi) and Dexamethasone | Eisai | Phase 2 | 27 |
| GLIADEL | Eisai | Phase 2 | 35 |
| Nivolumab + Temozolomide | Ono Pharmaceutical | Phase 3 | 40 |
| Prexasertib + Cyclophosphamide + Gemcitabine + filgrastim + peg-filgrastim | Eli Lilly | Phase 1 | 29 |
| abemaciclib + abemaciclib | Eli Lilly | Phase 2 | 39 |
| JNJ-17299425 | Johnson & Johnson | Phase 2 | 27 |
| ABT-888 | AbbVie | Phase 1 | 29 |
| Veliparib + Placebo | AbbVie | Phase 2 | 35 |
| Iressa (Gefitinib) | AstraZeneca | Phase 2 | 27 |
| Trastuzumab deruxtecan | AstraZeneca | Phase 2 | 42 |
| Exenatide | AstraZeneca | Approved | 43 |
| AZD5213 | AstraZeneca | Phase 1 | 29 |
| Vorinostat | Merck | Phase 1 | 29 |